Patents Assigned to Chengdu Kanghong Biotechnology Co. Ltd.
  • Method for treating angiogenic eye disorders using VEGF antagonists
    Patent number: 11944663
    Abstract: The present patent application provides methods for treating patients having angiogenic eye disorder by administering a VEGF antagonist, particularly an VEGF antagonist comprising the amino acid sequence of SEQ ID NO:1 in one or more treatment phases.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: April 2, 2024
    Assignee: Chengdu Kanghong Biotechnologies Co. Ltd.
    Inventor: Zunhong Ke
  • RECOMBINANT ADENO-ASSOCIATED VIRUS FOR DELIVERY OF KH902 (CONBERCEPT) AND USES THEREOF
    Publication number: 20230057380
    Abstract: Aspects of the disclosure relate to a recombinant adeno-virus encoding an anti-Vascular endothelial cell growth factor (VEGF) agent in a cell or subject (e.g., rAAV2.7m8-KH902). In some embodiments, compositions described herein are useful for treating subjects having diseases associated with angiogenesis or aberrant VEGF activity/signaling.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 23, 2023
    Applicants: University of Massachusetts, Chengdu Kanghong Biotechnology Co. Ltd.
    Inventors: Guangping Gao, Phillip Tai, Claudio Punzo, Zunhong Ke
  • Method For Treating Angiogenic Eye Disorders Using Vegf Antagonists
    Publication number: 20210393738
    Abstract: The present patent application provides methods for treating patients having angiogenic eye disorder by administering a VEGF antagonist, particularly an VEGF antagonist comprising the amino acid sequence of SEQ ID NO:1 in one or more treatment phases.
    Type: Application
    Filed: June 18, 2021
    Publication date: December 23, 2021
    Applicant: Chengdu Kanghong Biotechnologies Co. Ltd.
    Inventor: Zunhong Ke
  • Fusion protein inhibiting angiogenesis or growth and use thereof
    Patent number: 9657084
    Abstract: Provided are a fusion protein inhibiting angiogenesis or vascular growth, coding sequence thereof, vector comprising the coding sequence, host cell, pharmaceutical composition and use of the fusion protein. The fusion protein of the present invention has high thermostability, and has a dramatic decline in the protein aggregation formation rate in a fermentation process, and a significant increase in the purity and yield of the protein, and has better biological activity.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: May 23, 2017
    Assignee: Chengdu Kanghong Biotechnologies Co., LTD.
    Inventors: Xiao Ke, Xiaoping Gao
  • Humanized anti-TNF-? antibody and antigen-binding fragment (Fab) thereof and use of the same
    Patent number: 9096669
    Abstract: The present invention discloses a humanized anti-human tumor necrosis factor-? antibody and antigen-binding fragment (Fab) thereof. The present invention also discloses a composition comprising the said antibody or antigen-binding fragment (Fab) thereof, and the use of the said antibody or antigen-binding fragment (Fab) thereof in treating the diseases associated with tumor necrosis factor-?.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: August 4, 2015
    Assignee: CHENGDU KANGHONG BIOTECHNOLOGIES CO., LTD.
    Inventors: Xiao Ke, Xiaoping Gao
  • Humanized Anti-TNF-alpha Antibody and Antigen-Binding Fragment (Fab) Thereof and Use of the Same
    Publication number: 20140086904
    Abstract: The present invention discloses a humanized anti-human tumor necrosis factor-? antibody and antigen-binding fragment (Fab) thereof. The present invention also discloses a composition comprising the said antibody or antigen-binding fragment (Fab) thereof, and the use of the said antibody or antigen-binding fragment (Fab) thereof in treating the diseases associated with tumor necrosis factor-?.
    Type: Application
    Filed: September 30, 2011
    Publication date: March 27, 2014
    Applicant: Chengdu Kanghong Biotechnologies, Co., Ltd.
    Inventors: Xiao Ke, Xiaoping Gao
  • Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
    Patent number: 8216575
    Abstract: Described herein are novel soluble chimeric fusion proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including domain 4 of KDR. The claimed chimeric fusion proteins antagonize the endothelial cell proliferative and angiogenic activity of VEGF and are useful in the treatment of neovascularization-related disease.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: July 10, 2012
    Assignee: Chengdu Kanghong Biotechnologies Co., Ltd.
    Inventor: Michael Dechao Yu
  • Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor GM-CSF in tumor cells and uses thereof
    Patent number: 7951585
    Abstract: The present invention relates to gene therapy for tumors, specifically, it relates to the construction of oncolytic adenovirus recombinant, which specifically expresses immune modulatory factor GM-CSF in tumor cells and uses thereof.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: May 31, 2011
    Assignee: Chengdu Kanghong Biotechnologies Co., Ltd.
    Inventor: Zunhong Ke
  • Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
    Publication number: 20100272719
    Abstract: Described herein are novel soluble chimeric fusion proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including domain 4 of KDR. The claimed chimeric fusion proteins antagonize the endothelial cell proliferative and angiogenic activity of VEGF and are useful in the treatment of neovascularization-related disease.
    Type: Application
    Filed: June 11, 2009
    Publication date: October 28, 2010
    Applicant: CHENGDU KANGHONG BIOTECHNOLOGIES CO., LTD.
    Inventor: Michael Dechao Yu
  • ANGIOGENESIS-INHIBITING CHIMERIC PROTEINS AND THE USE
    Publication number: 20100215655
    Abstract: The present invention is directed to DNA sequence encoding angionenesis-inhibiting recombinant chimeric protein, the chimeric protein per se, the pharmaceutical use of the chimeric protein, and to the pharmaceutical composition containing the recombinant protein and the formulation thereof.
    Type: Application
    Filed: May 4, 2010
    Publication date: August 26, 2010
    Applicant: CHENGDU KANGHONG BIOTECHNOLOGIES CO. LTD.
    Inventors: Jianmin FANG, Zheng LIU, Dechao YU
  • Angiogenesis-inhibiting chimeric protein and the use
    Patent number: 7750138
    Abstract: The present invention is directed to DNA sequence encoding angiogenesis-inhibiting recombinant chimeric protein, the chimeric protein per se, the pharmaceutical use of the chimeric protein, and to the pharmaceutical composition containing the recombinant protein and the formulation thereof.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: July 6, 2010
    Assignee: Chengdu Kanghong Biotechnologies Co. Ltd.
    Inventors: Jianmin Fang, Zheng Liu, Dechao Yu
  • Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof
    Publication number: 20100047208
    Abstract: The present invention relates to gene therapy for tumors, specifically, it relates to the construction of oncolytic adenovirus recombinant, which specifically expresses immune modulatory factor GM-CSF in tumor cells and uses thereof.
    Type: Application
    Filed: November 19, 2004
    Publication date: February 25, 2010
    Applicant: CHENGDU KANGHONG BIOTECHNOLOGIES CO., LTD
    Inventor: Zunhong Ke
  • VEGF RECEPTOR FUSION PROTEINS, THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS FOR THE EYE DISEASES
    Publication number: 20090264358
    Abstract: Vascular endothelial growth factor (VEGF) receptor fusion protein comprising Ig domain 2 of Flt-1 and Ig domains 3, or Ig domain 2 of Flt-1 and Ig domain 3 and 4 of KDR, the gene encoding the fusion protein, the pharmaceutical composition containing the fusion protein and the pharmaceutical use of the fusion protein are provided. The fusion protein can be used for treatment of eye disorders involving angiogenesis such as diabetic retinopathy.
    Type: Application
    Filed: September 29, 2008
    Publication date: October 22, 2009
    Applicant: CHENGDU KANGHONG BIOTECHNOLOGIES, CO., LTD
    Inventor: Michael Dechao Yu